Growth in Specialty and Orphan Drug Approvals: The FDA’s focus on specialty medications and orphan drugs continues to expand, ...

In short, Moringa powder supplements are transforming immunity by providing a natural, nutritional armor for the body.

Global Healing's Oxy-Powder® demonstrated significant digestive health benefits in a recent Citruslabs study, with 95% of ...

Paris, France (2 April 2025) – EssilorLuxottica continues to grow and create value for shareholders. Following record-breaking investments in the SuperBoost 2025 international shareholding plan and ...

This news release is being issued by Dr. Sven Grail ("Dr. Grail") and Grail Family Foundation (the “Foundation”) as required by National Instrument 62-103 – The Early Warning System and Related ...

TeamHealth, a physician-founded and led practice of 18,000 clinicians and operational team members partnering with more than 2,400 hospitals and facilities, today announced a strategic partnership ...

Patent protection for ZORYVE cream 0.3% extends until at least 2037. ZORYVE cream 0.3% is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and ...

Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2025 first quarter results after market close on Tuesday, May 6, 2025. Nitin Jain, President and ...

ORLANDO, Fla., April 02, 2025 (GLOBE NEWSWIRE) -- AssistRx, the advanced therapy initiation and patient solutions provider, today announced it has completed an asset acquisition from AllazoHealth, a ...

The Acquisition follows the purchase of the remaining 30% interest in Nicola Lodge in Metro Vancouver on February 28, 2025, increasing Sienna’s ownership in the 256-bed best-in-class long-term care ...

Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The trial ...